Anti-Leucine-Rich Glioma-Inactivated Protein 1

Leucine-rich glioma-inactivated protein 1 (LGI1) is important for communication between brain cells, as it helps connect proteins on both sides of the synapse. 

When the body produces anti-LGI1 antibodies, it can interfere with this communication, causing symptoms like memory problems, seizures, and changes in behavior. In some cases, it may be linked to cancer or other serious health issues.

What is Leucine-Rich Glioma-Inactivated Protein 1 (LGI1)?

LGI1 (Leucine-rich Glioma Inactivated 1) is a protein that plays an important role in the brain's synaptic function. 

It is secreted from the presynaptic terminals of neurons and binds to two key proteins: ADAM23 (on the presynaptic side) and ADAM22 (on the postsynaptic side). These interactions help organize a complex that supports proper communication between neurons. 

LGI1 regulates channels that ensure smooth signaling across synapses, which is essential for processes associated with the limbic system, such as memory, learning, and emotional regulation. 

When anti-LGI1 antibodies are present, they can disrupt these interactions, impairing neuronal communication and leading to symptoms such as seizures, cognitive decline, and psychiatric disturbances, often seen in conditions like anti-LGI1 encephalitis.

What is Anti-LGI1?

Anti-LGI1 is an autoantibody that targets leucine-rich glioma-inactivated protein 1 (LGI1). 

When the body produces Anti-LGI1, this disrupts neuronal communication, leading to neurological dysfunction and physical and psychiatric symptoms. 

Anti-LGI1 testing is most commonly used to diagnose autoimmune encephalitis, particularly limbic encephalitis, marked by cognitive issues, seizures, and behavioral changes.

What Is Anti-LGI1 Encephalitis?

Anti-LGI1 encephalitis is a rare autoimmune disorder marked by the presence of anti-LGI1 antibodies in serum and cerebrospinal fluid (CSF), leading to seizures, cognitive impairment, psychiatric symptoms, and sleep disturbances. 

It primarily affects a part of the brain called the temporo-mesial lobe, causing symptoms like short-term memory loss, faciobrachial dystonic seizures (FBDS; these are a type of seizure that causes sudden, involuntary muscle contractions in the face and arm, often occurring together), psychiatric symptoms and hyponatremia. 

Although more common in adults, pediatric cases are increasing and often present with isolated symptoms that can look different than adult cases, making diagnosis challenging. 

The condition is also linked to paraneoplastic syndromes, raising the risk of malignancies.

Diagnosis and Treatment

Diagnosis relies on detecting anti-LGI1 antibodies in serum and/or cerebrospinal fluid (CSF), with serum tests showing a higher positivity rate (99.79% compared to 77.38% in CSF).

Neuroimaging typically reveals temporal lobe abnormalities, though atypical findings can occur, requiring high suspicion. 

Treatment involves immunosuppressive therapies such as corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange (PE) for severe cases, with rituximab and mycophenolate mofetil used in refractory or recurrent cases. 

Early detection is essential for initiating timely treatment, improving outcomes, and preventing long-term cognitive impairment. Regular follow-ups and malignancy screening are also necessary, especially in patients with paraneoplastic syndrome.

Who Should Get Tested?

The following groups of people may benefit from anti-LGI1 screening:

Patients with Neurological Symptoms

Individuals with sudden, unexplained memory loss, confusion, or behavioral changes should consider testing, especially if they have drug-resistant seizures or focal epilepsy of unknown origin.

Patients with Suspected Autoimmune Encephalitis

For those exhibiting personality changes, psychosis, or rapid cognitive decline, Anti-LGI1 testing can help identify autoimmune causes before significant neurological damage occurs.

At-Risk Populations

Rarely, anti-LGI1 encephalitis may be associated with paraneoplastic syndrome. Individuals with a history of cancer or recurrent symptoms may need further assessment.

Healthcare Providers Diagnosing Neurological Conditions

Neurologists and psychiatrists can use Anti-LGI1 testing to differentiate autoimmune from non-autoimmune causes of encephalitis and guide treatment decisions.

Test Procedure and Interpretation

Anti-LGI1 may be assessed in serum or CSF, with serum having a higher predictive value.

Anti-LGI1 in serum is typically assessed using an Immunofluorescence Assay (IFA). No special patient preparation is required for the test, though it may be most effective when symptoms of acute encephalitis or ongoing neurological changes are present. 

Reference Ranges

Reference ranges for Anti-LGI1 vary by laboratory, but a negative result generally indicates no presence of the autoantibody. 

However, a negative result should be considered alongside clinical symptoms and other diagnostic tests, as results can be influenced by disease stage or prior treatment.

Clinical Implications of Elevated Anti-LGI1

Elevated Anti-LGI1 levels indicate active autoimmune encephalitis, especially limbic encephalitis. 

Rarely, high levels may also indicate the presence of paraneoplastic syndromes in patients with underlying malignancies.

If left untreated, high levels of Anti-LGI1 can lead to chronic neurological impairments, as persistent inflammation may cause irreversible damage to the hippocampus and other structures of the limbic system. 

Early intervention with immunosuppressive therapies is essential to prevent long-term damage. Regular monitoring of Anti-LGI1 levels can help evaluate the patient’s response to treatment and prevent relapses.

Clinical Implications of Low Levels of Anti-LGI1

While low or negative Anti-LGI1 levels are generally associated with the absence of autoimmune encephalitis, they do not exclude the diagnosis, particularly in the early stages of the disease or when the patient has received prior immunosuppressive treatment. 

Negative results may suggest alternative diagnoses, such as viral encephalitis, neurodegenerative diseases, or psychiatric disorders. Additional diagnostic tools like cerebrospinal fluid analysis, MRI, and other biomarkers should be used to confirm the diagnosis.

It’s also important to note that false negatives can occur, so a comprehensive diagnostic approach is necessary. Early-stage disease or immunosuppressive therapy before testing may result in falsely low Anti-LGI1 levels.

Order Antibody Testing

Click here to compare testing options and order antibody test panels.